



Human Papilloma Virus (HPV)—Cervical Cancer Prevention, Screening, and Treatment

Guest Editor:

Prof. Dr. Kouya Shiraishi

Division of Genome Biology,
National Cancer Center Research
Institute, 5-1-1 Tsukiji, Chuo-ku,
Tokyo 104-0045, Japan

Deadline for manuscript
submissions:

closed (10 September 2023)

Message from the Guest Editor

Dear Colleagues,

Cervical cancer is the fourth most common cancer among women worldwide, and the fourth most common cause of cancer-related deaths. It is primarily caused by persistent infection by carcinogenic strains of human papillomavirus (HPV), especially strains 16 and 18. Although safe and effective prophylactic vaccines against the most carcinogenic forms of HPV are widely available, the HPV vaccination rate in low- and middle-income countries is low compared with that of other routine childhood immunizations. HPV vaccine recommendations were resumed in 2022, but it will take more than 10 years for the vaccination efforts to translate into a tangible and effective reduction in cervical cancer incidence rates, since the target age group for vaccination is 12–16 years old. Therefore, continued research into prevention, screening, and novel treatments for HPV-associated cervical cancer is required during this lag period, especially in countries where vaccination is still not widely available. In this Special Issue, the latest developments in this field will be presented.

Prof. Dr. Kouya Shiraishi

Guest Editor





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)